BrainChild Bio closed a $116 million Series A to advance its Phase 2 DIPG trial and develop additional CAR T cell therapies for brain tumors.
- Amount
- $116M
- Stage
- Series A
- Announced
- 8 September 2026
- Lead
- An undisclosed private family fund and foundation
- Other investors
- Seattle Children's, WRF Capital
- Use of funds
- Support the ILLUMINATE Phase 2 study of BCB-276 and early pipeline programs
- Checked
- Announced by the company